iData Insights

Metastatic Pancreatic Cancer - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 30, 2016 15:17 IST

Metastatic Pancreatic Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct s, Metastatic Pancreatic Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Pancreatic Cancer s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Metastatic Pancreatic Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Metastatic Pancreatic Cancer - Overview 11

Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12

Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13

Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 18

Metastatic Pancreatic Cancer - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Metastatic Pancreatic Cancer - Products under Development by Companies 22

Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 27

Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 28

AbbVie Inc. 28

Aduro BioTech, Inc. 29

ArQule, Inc. 30

Array BioPharma Inc. 31

AstraZeneca Plc 32

AVEO Pharmaceuticals, Inc. 33

Axcentua Pharmaceuticals AB 34

Biothera, Inc. 35

Boehringer Ingelheim GmbH 36

Boston Biomedical, Inc. 37

Bristol-Myers Squibb Company 38

Cantex Pharmaceuticals, Inc. 39

Celgene Corporation 40

Clovis Oncology, Inc. 41

Cornerstone Pharmaceuticals, Inc. 42

CTI BioPharma Corp. 43

CytRx Corporation 44

Eleison Pharmaceuticals, Inc. 45

Eli Lilly and Company 46

Ensol Biosciences Inc. 47

Erytech Pharma SA 48

F. Hoffmann-La Roche Ltd. 49

Fountain Biopharma Inc. 50

Gilead Sciences, Inc. 51

GlaxoSmithKline Plc 52

Halozyme Therapeutics, Inc. 53

HanAll Biopharma Co., Ltd. 54

Immodulon Therapeutics Ltd. 55

Immunomedics, Inc. 56

Incyte Corporation 57

MabVax Therapeutics Holdings, Inc. 58

MedImmune, LLC 59

Merck & Co., Inc. 60

Merrimack Pharmaceuticals, Inc. 61

NanoCarrier Co., Ltd. 62

Nanotherapeutics, Inc. 63

NantKwest, Inc. 64

Natco Pharma Limited 65

NewLink Genetics Corporation 66

Novartis AG 67

Oncolytics Biotech Inc. 68

Oncovir, Inc. 69

Oryx GmbH & Co. KG 70

Pfizer Inc. 71

Pharma Mar, S.A. 72

Pharmacyclics, Inc. 73

Phoenix Biotechnology, Inc. 74

Precision Biologics, Inc. 75

Redx Pharma Plc 76

Rexahn Pharmaceuticals, Inc. 77

Sanofi 78

Silence Therapeutics Plc 79

Targovax AS 80

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.